On the occasion of World Hepatitis Day, ECDC launched online prevalence database for hepatitis B and C which included data mainly based on peer-reviewed cross sectional studies from 2006 onwards.
Since its introduction in the 1990s, the main aim of combination antiretroviral therapy (ART) for HIV has been to halt the progression of the infection, maintaining the health of the HIV-positive person taking treatment. In addition to this, the impact of treatment as prevention has been well described.
People in prison experience a higher burden of communicable diseases such as hepatitis B (HBV), hepatitis C (HCV) and HIV often linked to a history of injecting drug use.
In their joint public health Guidance published today, ECDC and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), present the evidence on active case finding as a key measure to diagnose communicable diseases early.
Can whole genome sequencing illustrate changes in drug susceptibility of gonorrhoea to antimicrobials used for treatment and so help to define more effective treatment regimens?
Within a matter of weeks, three cases of gonorrhoea that are resistant to the recommended first line antibiotic treatment have been detected in Europe and Australia. These are the first global reports of Neisseria gonorrhoeae with high-level resistance to azithromycin and ceftriaxone resistance that also show resistance to several other vital antibiotics. At a time with limited alternatives to the current dual therapy, lack of a vaccine and insufficient surveillance capacity in some regions, these cases highlight the growing threat of drug-resistance – which could lead to untreatable gonorrhoea.
Bacteria from humans and animals continue to show resistance to antimicrobials, according to a new report published today by the European Food Safety Authority and the European Centre for Disease Prevention and Control. The report highlights some emerging issues and confirms antimicrobial resistance as one of the biggest threats to public health. AMR reduces the effectiveness of treatment options.
One in 2 people living with HIV are diagnosed late in the course of their infection. So late, that two out of three people with AIDS in the EU/EEA receive their diagnosis within only three months of discovering they had HIV. For World AIDS Day 2017, ECDC highlighted the problem of late diagnosis and the need for diversifying HIV testing approaches.
The WHO European Region is the only Region worldwide where the number of new HIV infections is rising. With more than 160 000 people newly diagnosed with HIV across the Region, including more than 29 000 new cases from the European Union and European Economic Area (EU/EEA), this trend continued in 2016.